Camostat
- Generic Name
- Camostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N4O5
- CAS Number
- 59721-28-7
- Unique Ingredient Identifier
- 0FD207WKDU
- Background
Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment...
- Indication
用于慢性胰腺炎的急性症状缓解。
- Associated Conditions
- -
- Associated Therapies
- -
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 44
- Registration Number
- NCT04730206
- Locations
- 🇧🇪
KU Leuven, Leuven, Belgium
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 2
- Registration Number
- NCT04662073
- Locations
- 🇺🇸
ValleyCare Medical Center, Pleasanton, California, United States
🇺🇸Stanford University, Stanford, California, United States
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 122
- Registration Number
- NCT04662086
- Locations
- 🇺🇸
ValleyCare Medical Center, Pleasanton, California, United States
🇺🇸Stanford University, Stanford, California, United States
The Potential of Camostat in COVID-19
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 108
- Registration Number
- NCT04625114
- Locations
- 🇧🇪
Ghent University Hospital, Algemene Inwendige Ziekten, Gent, Belgium
ACTIV-2: A Study for Outpatients With COVID-19
- Conditions
- Interventions
- Biological: bamlanivimab 7000mgDrug: Placebo for Bamlanivimab 7000mgBiological: bamlanivimab 700mgDrug: Placebo for Bamlanivimab 700mgBiological: BRII-196+BRII-198Drug: Placebo for BRII-196+BRII-198Biological: AZD7442 (IV)Drug: Placebo for AZD7442 (IV)Biological: AZD7442 (IM)Drug: Placebo for AZD7442 (IM)Drug: Placebo for SNG001Drug: Placebo for CamostatBiological: SAB-185 (3,840 Units/kg)Drug: Placebo for SAB-185 (low dose)Drug: CASIRIVIMAB + IMDEVIMABBiological: SAB-185 (10,240 Units/kg)Drug: Placebo for SAB-185 (high dose)Biological: BMS-986414 + BMS-986413Drug: Placebo for BMS-986414 + BMS-986413Drug: SNG001Drug: Camostat
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-08-02
- Target Recruit Count
- 4044
- Registration Number
- NCT04518410
- Locations
- 🇺🇸
Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B, Atlanta, Georgia, United States
🇺🇸Baltimore VA Medical Center (Site 1258), 10 N. Greene St., Baltimore, Maryland, United States
🇺🇸Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 34
- Registration Number
- NCT04455815
- Locations
- 🇬🇧
The Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
🇬🇧Church Avenue Medical Group, Harrogate, United Kingdom
🇬🇧Clarence Medical Centre, Rhyl, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.